<DOC>
	<DOCNO>NCT00096486</DOCNO>
	<brief_summary>RATIONALE : Gefitinib everolimus may stop growth tumor cell block enzymes necessary growth . Giving gefitinib together everolimus may kill tumor cell . PURPOSE : This phase I/II trial study side effect , best way give , best dose give gefitinib everolimus see well work treat patient stage IIIB stage IV recurrent non-small cell lung cancer .</brief_summary>
	<brief_title>Gefitinib Everolimus Treating Patients With Stage IIIB Stage IV Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose everolimus administer gefitinib patient stage IIIB IV recurrent non-small cell lung cancer . ( Phase I ) - Determine efficacy regimen patient . ( Phase II ) Secondary - Assess pharmacokinetics everolimus , alone combination gefitinib , patient . ( Phase I ) OUTLINE : This open-label , phase I , dose-escalation study everolimus follow phase II study . - Phase I : Patients receive oral everolimus day 1 . Beginning day 8 , patient receive oral gefitinib daily . Beginning day 22 , patient receive oral everolimus daily . Both drug give concurrently rest treatment . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos everolimus maximum tolerate dose ( MTD ) determine . The MTD define dose 1 6 patient experience dose-limiting toxicity . - Phase II : Patients receive oral everolimus MTD determine phase I oral gefitinib daily . Treatment continue absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer ( NSCLC ) meet 1 follow stage criterion : Stage IIIB ( unresectable , malignant pleural pericardial effusion ) Stage IV disease Recurrent disease Measurable evaluable indicator lesion Progressive disease receive ≥ 1 prior chemotherapy regimen include cisplatin carboplatin docetaxel No uncontrolled brain leptomeningeal metastasis Must require concurrent glucocorticoid control metastases PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % OR ECOG 02 Life expectancy Not specify Hematopoietic WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 2.5 time ULN Renal Creatinine ≤ 1.5 time ULN OR Creatinine clearance ≥ 60 mL/min Cardiovascular No congestive heart failure No New York Heart Association class III IV heart disease No unstable angina Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No severe infection No severe malnutrition No serious medical illness No malignancy within past 3 year except adequately treat basal cell squamous cell skin cancer carcinoma cervix PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent biologic therapy No concurrent immunotherapy Chemotherapy See Disease Characteristics No prior conventional chemotherapy metastatic recurrent NSCLC ( phase II ) At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy See Disease Characteristics No concurrent oral steroid management skin toxicity Radiotherapy At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery At least 4 week since prior major surgery No concurrent surgery identifiable lesion Other Recovered prior therapy No prior gefitinib , erlotinib , epidermal growth factor tyrosine kinase inhibitor No concurrent cytotoxic therapy ( e.g. , methotrexate rheumatoid arthritis ) No concurrent oncolytic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>